United Therapeutics to Showcase Tyvaso DPI Clinical Data at PVRI 2025
United Therapeutics Corporation (Nasdaq: UTHR) is set to present five posters at the Pulmonary Vascular Research Institute (PVRI) 2025 Annual Congress, taking place from January 29 to February 1, 2025, in Rio de Janeiro. The presentations will focus on the clinical application and outcomes of Tyvaso DPI, a treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Key Presentations
- Real-World Dosing of Tyvaso DPI: This poster will discuss the practical dosing strategies for Tyvaso DPI in patients with PAH and PH-ILD, providing insights into its application outside of clinical trial settings.
- BREEZE Open-Label Extension Study: Findings from this study will detail the long-term outcomes and dosing of Tyvaso DPI in patients with PAH, offering valuable data on its sustained efficacy and safety.
- PHINDER Study Interim Results: Early data from the PHINDER study will be shared, highlighting efforts to detect pulmonary hypertension in patients with interstitial lung disease more efficiently.
- TRIUMPH Study Sub-Group Analysis: This analysis will focus on the use of inhaled treprostinil in intermediate-high risk PAH patients, shedding light on its effectiveness in this subgroup.
- ARTISAN Study Patient Experience: Insights into the patient-reported experiences from the ARTISAN study will be presented, emphasizing the impact of Tyvaso DPI on quality of life.
Speaking Engagements and Sponsored Events
United Therapeutics will also participate in two speaking events at the congress, focusing on real-world evidence and the challenges of clinical trial design. Additionally, the company is proud to sponsor the Women in PH Luncheon and the Career Catalyst Luncheon, aimed at supporting educational opportunities and professional networking for women and early-career professionals in the pulmonary hypertension field.
About Tyvaso DPI
Tyvaso DPI (treprostinil) Inhalation Powder is indicated for the treatment of PAH and PH-ILD to improve exercise ability. It is a prostacyclin mimetic that has shown efficacy in patients with NYHA Functional Class III symptoms and specific etiologies of PAH and PH-ILD. The treatment's effects are known to diminish over the minimum recommended dosing interval of 4 hours, allowing for adjustments based on planned activities.
Important Safety Information
Patients using Tyvaso DPI should be aware of potential risks, including symptomatic hypotension, increased bleeding risk, and acute bronchospasm, especially in those with asthma or COPD. The drug's interaction with CYP2C8 enzyme inhibitors or inducers may alter its exposure levels, affecting its safety and efficacy.
For more detailed information on Tyvaso DPI, including full prescribing information and instructions for use, healthcare professionals and patients are encouraged to visit the official website or contact United Therapeutics directly.
United Therapeutics continues to lead in the development of innovative treatments for pulmonary hypertension, reinforcing its commitment to improving patient outcomes and advancing the field of pulmonary vascular disease.
